Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Date:12/12/2012

ectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The program also includes a study in patients who have or are at high risk for developing cardiovascular disease, called the CANagliflozin cardioVascular Assessment Study (CANVAS).

Janssen presented data from Phase 3 studies at the American Diabetes Association (ADA) in Philadelphia in June, at the European Association for the Study of Diabetes (EASD) in Berlin in October, and at the World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) in Barcelona in November.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, the Middle East, Africa, Australia, New Zealand and parts of Asia.

About Type 2 Diabetes

Type 2 diabetes is a chronic condition that affects the body's ability to metabolize sugar, or glucose, and is characterized by the inability of pancreatic beta cell function to keep up with the body's demand for insulin. People with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. In most people with type 2 diabetes, obesity causes resistance of the body to the action of insulin and if the pancreatic beta cell cannot produce enough insulin, hyperglycemia and type 2 diabetes ensue.

If left uncontrolled, type 2 diabetes can lead to serious long-term microvascular complications such as nerve disease leading to amputation, retinopathy resulting in blindness and nephropathy causing end-stage renal disease. Improved gl
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ALPHARETTA, Ga. , July 6, 2015  EndoChoice ... release its second quarter 2015 financial results on Thursday, ... EndoChoice will hold a conference call on Thursday, ... the results. The dial-in numbers are (866) 807-9684 for ... live webcast of the conference call will be available ...
(Date:7/6/2015)... July 6, 2015  OrthoSpace Ltd. ("OrthoSpace" or ... three patients in its US Investigational Device Exemption ... patient randomized, single blinded control study that compares ... repair or partial repair for the treatment of ... is currently commercially available outside of ...
(Date:7/6/2015)... , July 6, 2015 /CNW/ - The Canadian Pharmacists ... national immunization strategy to ensure that all Canadians have ... of HPV (human papillomavirus) through immunization. The lack of ... Canada is needlessly putting the ... diseases, such as HPV, continue to pose a significant ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2
... 2011  Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced ... Express breast cancer vaccine did not air yesterday ... December 16, 2011 promotional spot).  The Company will ... Television advise as to a rescheduled air date ...
... 2011 The in Thought™ research ... leading provider of scientific information and analytics, today ... cardiology pipeline that gives cardiologists and their patients ... in Thought,s Leon Henderson, "Innovative Medicine Shaping ...
Cached Medicine Technology:Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment 2Generex Provides Update on Bloomberg TV Breast Cancer Vaccine Segment 3inThought Report Says New Wave of Cardiology Drugs to Be Big Boon 2inThought Report Says New Wave of Cardiology Drugs to Be Big Boon 3inThought Report Says New Wave of Cardiology Drugs to Be Big Boon 4
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... For ... finding medical providers for personal injury victims. Throughout the company’s history the goal ... deliver the care victims need in their recovery. And while Doctors on Liens ...
(Date:7/6/2015)... ... July 06, 2015 , ... Respected southern California personal injury attorney Fernando ... him as an attorney who has sharp legal skills as well as a superior ... for 2015 from Martindale-Hubbell and a Top 10 Award from The National Academy of ...
(Date:7/6/2015)... ... , ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led ... newly available tests that better incorporate personalized medicine into diagnosing the condition. , ... is published in the July issue of the scientific journal Thyroid . ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... Shortly ... on Liens , the leading network of doctors working on a lien basis. ... Doctors on Liens. , The daughter of two Cambodian refugees, Dr. Lim suffered with ...
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
Breaking Medicine News(10 mins):Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3
... FAIRFAX, Va., Oct. 24 Kathleen M. Foley, ... City, and Perry Fine,MD, of the University of ... in Education and Leadership Award for 2007 at ... The award recognizes,contributors to the advancement of palliative ...
... improved efficacy and reduced toxicity, studies find, , , WEDNESDAY, ... chemotherapy drug, docetaxel, to the standard two-drug regimen used ... the treatment while reducing the toxicity, two new studies ... effective that it increased survival in both studies and ...
... Norway October 24, 2007 - The use of ... increased incidence of reproductive endocrine disorders in both men ... the effects of withdrawal from two common AEDs, carbamazepine ... and female AED users. , The study finds ...
... New research results from the University at Buffalos Research ... aware of and accurately evaluate the extent of their ... use., Researchers also found that in cases where parents ... twice as likely to underestimate frequency of marijuana use ...
... by needles, experts say , , WEDNESDAY, Oct. 24 (HealthDay ... can be given the nasal spray influenza vaccine FluMist, ... only recommended for healthy people ages 5 to 49. ... than 5, but the advisers said Wednesday that FluMist ...
... to Leverage Zagat,s, Expertise to Survey Physicians; WellPoint Members ... Rate Experiences Using Zagat,s Renowned 30-Point ... WellPoint, Inc., the,nation,s largest health benefits company, and Zagat ... online survey tool that will allow,consumers to share their ...
Cached Medicine News:Health News:Two Physicians Recognized for Work in Pain and Symptom Management 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 3Health News:Gauging parent knowledge about teens' substance use 2Health News:Gauging parent knowledge about teens' substance use 3Health News:U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children 2Health News:U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children 3Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 2Health News:WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: